Menu
With an eye on patients™
we are committed to developing solutions to help people facing serious eye disorders. At EyePoint Pharmaceuticals, you can see our dedication in action.
Nancy Lurker
President & Chief Executive Officer
Our President, CEO, and a director since September 2016, Ms Lurker has broad-ranging experience in the pharmaceutical industry and a track record of maximizing the potential of new therapies and successfully implementing innovative US and global drug launches.
Jay Duker, MD
Chief Strategic Scientific Officer
The Director of the New England Eye Center, Dr Jay Duker brings more than 30 years of ophthalmology experience to EyePoint with roles held in the clinical, research, and academic settings.
George O. Elston
Chief Financial Officer & Head of Corporate Development
Mr Elston brings more than 25 years of diverse financial and senior leadership experience in the biopharmaceutical sector with both global publicly traded and privately held organizations.
Ron Honig
Chief Legal Officer & Company Secretar
Mr Honig brings more than 25 years of legal experience in the medical device, biotechnology, contract manufacturing, and legal services industries to his role at EyePoint, which he has held since November 2018.
Scott Jones
Chief Commercial Officer
With a background in developing commercial and growth strategy, Mr Jones brings significant experience commercializing drugs and devices globally.
Jennifer Leonard
Senior Vice President of Human Resources and IT
Ms Leonard has over 25 years of successful executive coaching, organizational effectiveness, leadership development, talent management, and culture development experience.
Dario Paggiarino, MD
Senior Vice President & Chief Medical Officer
Dr Paggiarino joined EyePoint from Lpath, where he served as Senior Vice President and Chief Development Officer. Dr Paggiarino earned his degree in medicine and general surgery cum laude from the University of Rome La Sapienza and has authored numerous scientific articles.
Said Saim, PhD
Chief Technology Officer
Dr Saim has more than 25 years of product development experience. Dr Saim has published 22 papers in engineering and science journals, holds 18 patents, and earned a PhD in chemical engineering from the University of Kansas.
Jack Weet, PhD
Senior Vice President, Regulatory
Dr Weet brings to EyePoint over 40 years of experience in regulatory affairs. Dr Weet received a PhD in physiology from the Ohio State University College of Medicine. He completed his postdoctoral fellowship at the University of Iowa College of Medicine.
Nancy Lurker
President & Chief Executive Officer
Our President, CEO, and a director since September 2016, Ms Lurker has broad-ranging experience in the pharmaceutical industry and a track record of maximizing the potential of new therapies and successfully implementing innovative US and global drug launches.
Jay Duker, MD
Chief Strategic Scientific Officer
The Director of the New England Eye Center, Dr Jay Duker brings more than 30 years of ophthalmology experience to EyePoint with roles held in the clinical, research, and academic settings.
George O. Elston
Chief Financial Officer & Head of Corporate Development
Mr Elston brings more than 25 years of diverse financial and senior leadership experience in the biopharmaceutical sector with both global publicly traded and privately held organizations.
Ron Honig
Chief Legal Officer & Company Secretar
Mr Honig brings more than 25 years of legal experience in the medical device, biotechnology, contract manufacturing, and legal services industries to his role at EyePoint, which he has held since November 2018.
Scott Jones
Chief Commercial Officer
With a background in developing commercial and growth strategy, Mr Jones brings significant experience commercializing drugs and devices globally.
Jennifer Leonard
Senior Vice President of Human Resources and IT
Ms Leonard has over 25 years of successful executive coaching, organizational effectiveness, leadership development, talent management, and culture development experience.
Dario Paggiarino, MD
Senior Vice President & Chief Medical Officer
Dr Paggiarino joined EyePoint from Lpath, where he served as Senior Vice President and Chief Development Officer. Dr Paggiarino earned his degree in medicine and general surgery cum laude from the University of Rome La Sapienza and has authored numerous scientific articles.
Said Saim, PhD
Chief Technology Officer
Dr Saim has more than 25 years of product development experience. Dr Saim has published 22 papers in engineering and science journals, holds 18 patents, and earned a PhD in chemical engineering from the University of Kansas.
Jack Weet, PhD
Senior Vice President, Regulatory
Dr Weet brings to EyePoint over 40 years of experience in regulatory affairs. Dr Weet received a PhD in physiology from the Ohio State University College of Medicine. He completed his postdoctoral fellowship at the University of Iowa College of Medicine.
Göran Ando, MD
Chairman of the Board
Wendy DiCicco
Director
Ron Eastman
Director
Doug Godshall
Director
David Guyer, MD
Director
John Landis, PhD, MS
Director
Ye Liu
Director
Nancy Lurker
President & Chief Executive Officer
EyePoint and the EyePoint logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.
EyePoint and the EyePoint logo are registered trademarks of EyePoint Pharmaceuticals, Inc. With an Eye on Patients is a trademark of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.
EyePoint, the EyePoint logo, and Delivering Innovation to the Eye are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.
EyePoint, the EyePoint logo, YUTIQ, Durasert, and DEXYCU are registered trademarks of EyePoint Pharmaceuticals, Inc. Verisome is a registered trademark of Ramscor, Inc. All other trademarks are the property of their respective owners.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.
EyePoint, the EyePoint logo, YUTIQ, and Durasert are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.
EyePoint, the EyePoint logo, the YUTIQ logo, and the DEXYCU logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.
EyePoint, the EyePoint logo, YUTIQ, the YUTIQ logo, and Durasert are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.
EyePoint, the EyePoint logo, DEXYCU, and the DEXYCU logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.
EyePoint, the EyePoint logo, Durasert, YUTIQ, and DEXYCU are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.
EyePoint, the EyePoint logo, YUTIQ, and DEXYCU are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.